September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion.
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with
Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum.
Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises.
